Kardigan raises $400m in upsized IPO at $16 per share

Kardigan Inc., a cardiovascular precision therapeutics company led by the former management team of MyoKardia, raised $400 million in an upsized initial public offering, pricing 25 million shares at $16 apiece.

The company develops medicines targeting the root cause of specific cardiovascular diseases where no approved treatments exist, Kardigan said in a statement. The offering was upsized from an undisclosed original target, reflecting demand that included anchor-type orders from long-only investors, according to a Bloomberg report.

The South San Francisco and Princeton, New Jersey-based biotech granted underwriters a 30-day option to purchase up to an additional 3.75 million shares at the IPO price. J.P. Morgan, Jefferies, Leerink Partners and TD Securities are serving as joint bookrunners. The offering is expected to close on June 22.

Kardigan's debut comes as the biotech IPO market shows signs of revival. The company's leadership previously built MyoKardia, which Bristol Myers Squibb acquired for $13.1 billion in 2020. Kardigan's pipeline targets cardiovascular diseases with no approved therapies, a strategy that will require years of clinical development and significant capital investment before any potential revenue.

The company's cash position was not disclosed in the IPO filing, but the $400 million gross proceeds provide a substantial runway for a clinical-stage biotech. Kardigan's focus on precision therapeutics — matching specific genetic or biomarker-defined patient populations to targeted treatments — mirrors the approach that made MyoKardia an attractive acquisition target. The company has not yet disclosed which specific cardiovascular indications its lead programs target, beyond stating they address diseases where no approved treatments currently exist.

Shares of Kardigan began trading on the Nasdaq Global Market on June 18 under the ticker KARD. The successful pricing at the top of the marketed range signals strong institutional appetite for cardiovascular-focused biotech platforms with proven management teams, a positive data point for other clinical-stage companies considering public listings.

This article is for informational purposes only and does not constitute investment advice.